Antibody production

Advanced Drug Delivery Reviews

Volumn 58, Issue 5-6, 2006, Pages 671-685

  Birch, John R ^a   Racher, Andrew J ^a  

^a LONZA AG   (Switzerland)

Author keywords

Cell line selection; CHO; Downstream processing; Fed batch culture; Fermentation; Gene expression systems; NS0

Indexed keywords

CELL CULTURE; CELLS; CHEMICAL REACTORS; COSTS; OPTIMIZATION;

CELL LINE SELECTION; CHO; DOWNSTREAM PROCESSING; FED-BATCH CULTURE; GENE EXPRESSION SYSTEMS;

ANTIBODIES;

GLUTAMATE AMMONIA LIGASE; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; CANCER CELL CULTURE; CELL CULTURE; CHO CELL; CLINICAL TRIAL; EXPRESSION VECTOR; FED BATCH CULTURE; FED BATCH REACTOR; FERMENTATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HYBRIDOMA; LYMPHOID CELL; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PRODUCTIVITY; PROTEIN EXPRESSION; REVIEW; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; DRUG INDUSTRY; GENETIC VECTORS; HUMANS; PROTEIN ENGINEERING; TRANSCRIPTION, GENETIC;

EID: 33747370959     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2005.12.006     Document Type: Review

References (62)

1. Winder R. Cell culture grows capacity. Chem. Ind. (17th October 2005) 21-22
2. Reichert J.C., Rosensweig C.J., Faden L.B., and Dewitz M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23 (2005) 1073-1078
3. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22 (2004) 1393-1398
4. Winder R. Cell culture changes gear. Chem. Ind. (17th October 2005) 18-20
5. J.R. Birch, D.O. Mainwaring, A.J. Racher, Use of the glutamine synthetase (GS) expression system for the rapid development of highly productive mammalian cell processes, in: J. Knäblein, (Ed.), Modern Biopharmaceuticals, WILEY-VCH Verlag GmbH and Co KGaA, Weinheim, (2005), pp. 809-832.
6. Smales C.M., Dinnis D.M., Stansfield S.H., Alete D.E., Sage E.A., Birch J.R., Racher A.J., Marshall C.T., and James D.C. Comparative proteomic analysis of GS-NS0 murine myeloma cell lines with varying recombinant monoclonal antibody production rate. Biotechnol. Bioeng. 88 (2004) 474-488
7. Lucas B.K., Giere L.M., DeMarco R.A., Shen A., Chisholm V., and Crowley C.W. High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector. Nucl. Acids Res. 24 (1996) 1774-1779
8. Jones D.H., Kroos N., Anema R., van Montfort B., Vooys A., van der Kraats S., van der Helm E., Smits S., Schouten J., Brouwer K., Lagerwerf F., van Berkel P., Opstelten D.-J., Logtenberg T., and Bout A. High-level expression of recombinant IgG in the human cell line PER.C6. Biotechnol. Prog. 19 (2003) 163-168
9. Bianchi A.A., and McGrew J.T. High-level expression of full-length antibodies using trans-complementing expression vectors. Biotechnol. Bioeng. 84 (2003) 439-444
10. Running Deer J., and Allison D.S. High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF1-α gene. Biotechnol. Prog. 20 (2004) 880-889
11. D.S. Allison, Hamster EF-1α transcriptional regulatory DNA. ICOS Corporation. 847218 [US 5888809] (1999).
12. M.E. Reff, Fully impaired consensus Kozac sequences for mammalian expression. IDEC Pharmaceuticals. PCT/US93/11221 [WO 94/11523] (1994).
13. Gillies S.D., Dorai H., Wesolowski J., Majeau G., Young D., Boyd J., Gardner J., and James K. Expression of human anti-tetanus toxoid antibody in transfected murine myeloma cells. Biotechnology 7 (1989) 799-804
14. G.F. Hollis, G.E. Mark, Homologous recombination antibody expression system for murine cells. PCT/IB95/00014 (1995).
15. Benton T., Chen T., McEntee M., Fox B., King D., Crombie R., and T.C.Thomas C.R. The use of UCOE vectors in combination with a preadapted serum free, suspension cell line allows for rapid production of large quantities of protein. Cytotechnology 38 (2002) 43-46
16. Kwaks T.H.J., Barnett P., Hemrika W., Siersma T.J., Sewalt R.G.A.B., Satijn D.P.E., Brons J.F., van Blokland R., Kwakman P., Kruckeberg A.L., Kelder A., and Otte A.P. Identification of anti-repressor elements that confer high and stable protein production in mammalian cells. Nat. Biotechnol. 21 (2003) 553-558
17. Kim J.-M., Kim J.-S., Park D.-H., Kang H.S., Yoon J., Baek K., and Yoon Y. Improved recombinant gene expression in CHO cells using matrix attachment regions. J. Biotechnol. 107 (2004) 95-105
18. Rendall M.H., Maxwell A., Tatham D., Khan P., Gay R.D., Kallmeier R.C., Wayte J.R.T., and Racher A.J. Transfection to manufacturing: reducing timelines for high yielding GS-CHO processes. In: Gòdia F., and Fussenegger M. (Eds). Animal Cell Technology Meets Genomics (2005), Springer, Dordrecht 701-704
19. Sinacore M.S., Charlebois T.S., Harrison S., Brennan S., Richards T., Hamilton M., Scott S., Brodeur S., Oakes P., Leonard M., Switzer M., Anagnostopoulos A., Foster B., Harris A., Jankowski M., Bond M., Martin S., and Adamson S.R. CHO DUKX cell lineages preadapted to growth in serum-free suspension culture enable rapid development of cell culture processes for the manufacture of recombinant proteins. Biotechnol. Bioeng. 52 (1996) 518-528
20. Barnes L.M., Bentley C.M., and Dickson A.J. Advances in animal cell recombinant protein production: GS-NS0 expression system. Cytotechnology 32 (2000) 109-123
21. Shulman M., Wilde C.D., and Köhler G.A. A better cell line for making hybridomas secreting specific antibodies. Nature 276 (1978) 269-270
22. Bebbington C.R., Renner G.L., Thomson S., King D., Abrams D., and Yarranton G.T. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Bio/Technology 10 (1992) 169-175
23. Köhler G., and Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. 6 (1976) 511-519
24. Inoue Y., Lopez L.B., Kawamoto S., Arita N., Teruya K., K.Seki M., Shoji M., Karmei S., Hashizume Y., Shiozawa H., Tachibana H., Ohashi K., Yasumoto T., Suzuki T., Imai K., Nomoto M., Takenoyama Y., and Katakura S. Production of recombinant human monoclonal antibody using ras-amplified BHK-21 cells in a protein-free medium. Biosci. Biotechnol. Biochem. 60 (1996) 811-817
25. Holmes P., and Al-Rubeai M. Improved cell line development by a high throughput affinity capture surface display technique to select for high secretors. J. Immunol. Methods 230 (1999) 141-147
26. Derouazi M., Girard P., van Tilborgh F., Iglesias K., Muller N., Bertschinger M., and Wurm F.M. Serum-free large-scale transient transfection of CHO cells. Biotechnol. Bioeng. 87 (2004) 537-545
27. Dinnis D.M., and James D.C. Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature?. Biotechnol. Bioeng 91 (2005) 180-189
28. Park K.-S., Seol W., Yang H.-Y., Lee S.I., Kim S.K., R.J.Kwon E.-J., Kim Y.-H., Roh B.L., and Seong J.S. Identification and use of zinc finger transcription factors that increase production of recombinant proteins in yeast and mammalian cells. Biotechnol. Prog. 21 (2005) 664-670
29. Arden N., and Betenbaugh M.J. Life and death in mammalian cell culture: strategies for apoptosis inhibition. Tibtech 22 (2004) 174-180
30. Yamane-Ohnuki N., Kinoshita S., Inoue-Urakubo M., Kusunoki M., Iida S., Nakano R., Wakitani M., Niwa R., Sakurada M., Uchida K., Shitara K., and Satoh M. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87 (2004) 614-622
31. Umaña P., Jean-Mairet J., Moudry R., Amstutz H., and Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimised antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17 (1999) 176-180
32. Davies J., Jiang L.Y., Pan L.-Z., LaBarre M.J., Anderson D., and Reff M.E. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII. Biotechnol. Bioeng 74 (2001) 288-294
33. Birch J.R. Cell products-antibodies. In: Spier R.G. (Ed). Encyclopaedia of Cell Technology (2000), Wiley 411-424
34. Chu D.L. Industrial choices for protein production by large-scale culture. Curr. Opin. Biotechnol. 12 (2001) 180-187
35. Voisard D., Meuwly F., Ruffieux P.-A., Baer G., and Kadouri A. Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnol. Bioeng. 82 (2003) 751-765
36. Deo Y.M., Mahadevan M.D., and Fuchs R. Practical considerations in operation and scale-up of spin-filter based bioreactors for monoclonal antibody production. Biotechnol. Prog. 12 (1996) 57-64
37. Singh V. Disposable bioreactor for cell culture using wave-induced agitation. Cytotechnology 30 (1999) 149-158
38. Sinclair A., and Monge M. Quantitative economic evaluation of single use disposables in bioprocessing. Pharm. Eng. 22 (2002) 20-34
39. Birch J.R., Bonnerjea J., and Flatman S. The production of monoclonal antibodies. In: Birch J.R., and Lennox E.S. (Eds). Monoclonal Antibodies: Principles and Applications (1995), Wiley 231-265
40. Varley J., and Birch J.R. Reactor design for large-scale suspension animal cell culture. Cytotechnology 29 (1999) 177-205
41. Wayte M., Boraston R., Bland H., Varley J., and Brown M. pH: effects on growth and productivity of cell lines producing monoclonal antibodies: control in large-scale fermenters. Genet. Eng. Biotechnol. 17 (1997) 125-132
42. Keen M.J. The culture of rat myeloma and rat hybridoma cells in a protein free medium. Cytotechnology 17 (1995) 193-202
43. Zang M., Trautmann H., Gandor C., Messi F., Asselbergs F., Leist C., Fiechter A., and Reiser J. Production of recombinant proteins in Chinese hamster cells using a protein-free cell culture medium. Bio/Technology 13 (1995) 389-392
44. Grima E.M., Chisti Y., and Moo-Young M. Characterisation of shear rates in airlift bioreactors for animal cell cultures. J. Biotechnol. 54 (1997) 195-210
45. Bibila T.A., and Robinson D.K. In pursuit of the optimal fed-batch process for monoclonal antibody production. Biotechnol. Prog. 11 (1995) 1-13
46. Dempsey J., Ruddock S., Osborne M., Ridley A., Sturt S., and Field R.P. Improved fermentation processes for NS0 cell lines expressing human antibodies and glutamine synthetase. Biotechnol. Prog. 19 (2003) 175-178
47. Sauer P.W., Burky J.E., Wesson M.C., Sternard H.D., and Qu L. A high-yielding, generic fed-batch culture process for production of recombinant antibodies. Biotechnol. Bioeng. 67 (2000) 585-597
48. Xie L., and Wang D.I.C. Integrated approaches to the design of media and feeding strategies for fed-batch cultures of animal cells. Trends Biotechnol. 15 (1997) 109-113
49. Glacken M.W., Fleischaker R.J., and Sinskey A.J. Reduction of waste product excretion via nutrient control: possible strategies for maximizing product and cell yields on serum in cultures of mammalian cells. Biotechnol. Bioeng. 28 (1986) 1376-1389
50. 2 and osmolality on growth of CHO cells and production of antibody-fusion protein B1: a case study. Biotechnol. Prog. 21 (2005) 70-77
51. Patel T.P., Parekh R.B., Moellering W.J., and Prior C.P. Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody. Biochem. J. 285 (1992) 839-845
52. Muthing J., Kemminer S.E., Conradt H.S., Sagi D., Nimtz M., Karst U., and Peter-Katalanic J. Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase 1 anti-melanoma mouse IgG3 monoclonal antibody R24. Biotechnol. Bioeng. 83 (2003) 321-334
53. Humphreys D. Production of antibodies and antibody fragments in Escherichia coli and a comparison of their functions uses and modification. Curr. Opin. Drug Discov. Dev. 6 (2003) 188-196
54. Bowering I.C. Microbial systems for the manufacture of therapeutic antibody fragments. Bioprocess Int. (June 2004) 40-47
55. Simmons L.C., Reilly D., Klimowski L., Raju T.S., Meng G., Sims P., Hong K., Shields R.L., Damico L.A., Rantacore P., and Yansura D.G. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J. Immunol. Methods 263 (2002) 133-147
56. Ward M. Expression of antibodies in Aspergillus niger. Genet. Eng. News 22 (2002) 48
57. Choi B.-K., Bobrowicz P., Davidson R.C., Hamilton S.R., Kung D.H., Li H., Miele R.G., Nett J.H., Wildt S., and Gerngross T.U. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. PNAS 100 (2003) 5022-5027
58. Ma J.K.-C., Drake P.M.W., and Christou P. The production of recombinant pharmaceutical proteins in plants. Nat. Rev. Genet. 4 (2003) 794-805
59. Pollock D.P., Kutzo J.P., Birck-Wilson E., Williams J.L., Echelard Y., and Meade H.M. Transgenic milk as a method for the production of recombinant antibodies. J. Immunol. Methods 231 (1999) 147-157
60. Chadd H.E., and Chamow S.M. Therapeutic antibody expression technology. Curr. Opin. Biotechnol. 12 (2001) 184-188
61. Berthold W., and Walter J. Protein purification: aspects of processes for pharmaceutical products. Biologicals 22 (1994) 135-150
62. Pavlou A.K., and Belsey M.J. The therapeutic antibodies market to 2008. Eur. J. Pharm. Biopharm. 59 (2005) 389-396